Sign In
Buy AXGN
$40.63
+1.17 (+2.97%)
At Close: Jun 03, 2026
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:25pm, Thursday, 15'th Jan 2026
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen CEO Axed 25,000 Shares From His Direct Holdings
07:07am, Wednesday, 14'th Jan 2026
Axogen's CEO sold 25,000 shares directly for $750,000 on Dec. 10, 2025. The sale represented 28.24% of the CEO's direct holdings prior to the transaction, reducing direct ownership to 63,537 shares (a
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
07:00am, Monday, 12'th Jan 2026
ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. grew its stake in shares of AxoGen, Inc. (NASDAQ: AXGN) by 26.0% during the third quarter, according to the company in its most recent disclosure with the Securities an
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
08:01pm, Wednesday, 03'rd Dec 2025
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of periph
FDA approves Axogen's nerve repair graft
06:53pm, Wednesday, 03'rd Dec 2025
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen
12:33pm, Monday, 01'st Dec 2025
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on
Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors
02:19pm, Wednesday, 05'th Nov 2025
The strongest contributor to Wasatch Micro Cap Value Fund performance for the quarter was Bel Fuse, Inc. Axogen, Inc. (AXGN) was also a top contributor, providing surgical solutions for peripheral ner
Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript
02:26pm, Wednesday, 29'th Oct 2025
Axogen, Inc. ( AXGN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Michael Dale - President, CEO & Director Lindsey Hartley - Chief Financial Officer Rick Ditto Jens Schroed
AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates
09:16am, Wednesday, 29'th Oct 2025
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
Axogen, Inc. Reports Third Quarter 2025 Financial Results
07:00am, Wednesday, 29'th Oct 2025
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
10:00am, Saturday, 18'th Oct 2025
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
01:42pm, Monday, 13'th Oct 2025
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
05:44pm, Wednesday, 08'th Oct 2025
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
10:00am, Friday, 03'rd Oct 2025
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact
